Rising colon cancer
Colorectal cancer (CRC) is the 4th most-diagnosed and 2nd-deadliest cancer in the United States. Overall incidence has fallen for decades thanks to screening — but cases in people under 50 are rising about 2% a year and have nearly doubled since the mid-1990s. CRC is now the leading cause of cancer death in men under 50 and the second leading cause in women under 50.
Source: ACS Cancer Facts & Figures 2024 · SEER Cancer Stat Facts (2026 projection: 158,850 new cases, 55,230 deaths).
The split
Screening colonoscopy and FIT testing in older adults has driven incidence down dramatically since the late 1980s. The opposite is happening in younger adults: birth cohorts born after 1960 carry meaningfully higher lifetime CRC risk than their parents did at the same age.
Note: Y-axis is age-adjusted incidence per 100,000. Source: SEER 9/12 registries, NCI; ACS CRC F&F 2023; Lancet Oncology 2024 (Bray et al.).
Geography
The states with the highest CRC incidence concentrate in Appalachia and the Lower Mississippi Delta — driven by obesity, smoking, type-2 diabetes prevalence, and lower screening uptake. The lowest-incidence states (Utah, Arizona, Colorado) combine younger populations with lower obesity rates. Range: 30.1–45.7 per 100,000.
Source: NCI State Cancer Profiles, age-adjusted invasive CRC incidence 2017–2021, both sexes, all races. A handful of low-population states are omitted for chart legibility.
Race & ethnicity
American Indian / Alaska Native adults have the highest CRC incidence in the US — roughly 60% higher than Asian / Pacific Islander adults. Black Americans are diagnosed younger and with more advanced disease than other groups, partly explaining a CRC mortality rate ~40% higher than that of white Americans.
Source: SEER 2017–2021, ACS CRC F&F 2023, Carethers JM, "Racial and Ethnic Disparities in CRC," Adv Cancer Res 2021.
Sex differences
Men carry ~30% higher CRC incidence than women across most age brackets. The biology is partly hormonal (estrogen appears mildly protective in the colon), partly behavioral (men in the US smoke more, drink more, and have higher rates of obesity and visceral fat). In adults under 50, the gap narrows but men still lead.
Source: SEER 2017–2021 (sex-specific, age-adjusted, all races).
Genetics
Most CRC is sporadic and accumulates mutations gradually from environmental and lifestyle exposures. But high-penetrance syndromes — especially Lynch syndrome — drive a meaningful slice of cases, particularly early-onset disease. Universal tumor screening for Lynch is now recommended for every new CRC diagnosis under 70.
Source: NCI PDQ Genetics of CRC; Mayo Clinic 2020; StatPearls "Hereditary CRC." Shares are illustrative ranges (literature: Lynch ~2–4%, FAP <1%, hereditary total 5–10%, familial clustering an additional ~15–20%).
Microbiome & infection
A wave of studies since 2020 has moved the microbiome from correlation to mechanism. The strongest signal is colibactin, a DNA-damaging toxin produced by pks+ strains of E. coli that leaves a fingerprint mutational signature in colon cells — and is over-represented in early-onset tumors. Fusobacterium nucleatum, ETBF, and Streptococcus gallolyticus also have plausible direct roles.
Detected in ~30–50% of CRC tumors vs ~5% of adjacent normal mucosa. Activates Wnt/β-catenin signalling, recruits myeloid suppressor cells, and predicts chemo resistance.
Genotoxin colibactin imprints a distinctive T>N mutational signature on the colon — found in ~50% of early-onset CRC tumors in a 2025 Nature study.
Secretes BFT toxin that cleaves E-cadherin, drives IL-17 inflammation; enriched in CRC biofilms.
Long-standing clinical association — bacteremia with this species warrants colonoscopy in ~50%+ of cases.
Chronic HBV/HCV elevate liver cancer risk; meta-analyses suggest a modest CRC excess via systemic inflammation, but the signal is small compared with HCC.
Sources: Pleguezuelos-Manzano et al. Nature 2020; Cao et al. Nature 2025 (colibactin signature in early-onset CRC); Brennan & Garrett, Annu Rev Microbiol 2019; British Journal of Cancer 2024.
Modifiable drivers
No single exposure explains the rise in younger adults — the pattern fits a multi-factor "exposome" that has shifted over generations: more childhood obesity and sedentary time, ultra-processed and high-sugar diets, antibiotic exposure altering the early-life microbiome, and rising rates of metabolic dysfunction.
Sources: IARC Monographs (red & processed meat = Group 2A/1); World Cancer Research Fund Continuous Update Project 2018; NutriNet-Santé cohort, BMJ 2022 (ultra-processed food and CRC).
Bottom line
USPSTF lowered the routine screening start age to 45 in 2021. Anyone with a first-degree relative diagnosed with CRC should start 10 years before that relative's diagnosis (and no later than 40).
Persistent rectal bleeding, change in bowel habits, iron-deficiency anemia, or unexplained weight loss in a younger adult deserves a colonoscopy — not reassurance.
Colibactin and Fusobacterium fingerprints are being developed as both diagnostic biomarkers and therapeutic targets — expect microbiome-targeted prevention trials this decade.
No single behavior cuts CRC risk dramatically, but the stack — body weight, alcohol, processed meat, fiber, activity, and not smoking — together explains an estimated 30–50% of preventable cases.
Build your personal screening checklist for the next 12 months — colonoscopy timing adjusts automatically for family history.